Outset Medical (OM) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Outset Medical (OM) has outperformed Stereotaxis (STXS) over the past year, losing 34.5% versus a loss of 59.4%. Over five years, STXS leads with a -84.2% price change compared with -99.6% for OM. Stereotaxis is the larger company by market cap ($95.0 million vs $53.0 million), about 1.8 times the size.
Stereotaxis converts more of its revenue into profit, with a net margin of -66.8% versus -68.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OM | STXS |
|---|---|---|
| Share price | $2.81 | $0.9422 |
| Market cap | $53.03M | $95.03M |
| 1-day change | -3.44% | -6.71% |
| YTD return | -24.26% | -59.03% |
| 1-year return | -34.50% | -59.39% |
| 5-year return | -99.61% | -84.16% |
| EPS (TTM) | $-3.78 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $119.48M | $32.38M |
| Revenue growth (YoY) | +5.09% | +20.28% |
| Net income (latest FY) | $-81.65M | $-21.64M |
| Gross margin | 39.13% | 52.73% |
| Operating margin | -55.83% | -68.30% |
| Net margin | -68.34% | -66.85% |
| 52-week high | $6.49 | $2.86 |
| 52-week low | $2.77 | $0.80 |
| Distance from 52-week high | -56.70% | -67.06% |
| Analyst consensus | buy | none |
| Avg. price target upside | +172.95% | +218.40% |
| Average volume | 140.40K | 715.12K |
| Shares outstanding | 18.87M | 100.86M |
| Employees | 310 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OM has outperformed STXS by 24.9 percentage points over the past year.
- Stereotaxis grew revenue faster in its latest fiscal year (+20.28% vs +5.09%).
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
OM vs STXS FAQ
Which is bigger, Outset Medical or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $95.03M compared with $53.03M for Outset Medical (OM).
Which stock has performed better over the past year, OM or STXS?
OM returned -34.50% over the past 12 months, compared with -59.39% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Outset Medical and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.